[
  {
    "ts": null,
    "headline": "Analysis-Novo Nordisk should look to the US for its next CEO, analysts say",
    "summary": "(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters.  Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.  Financial analysts Reuters spoke with said an American may be better placed to deal with a Trump administration, which is rewriting the rules on pharmaceutical trade, manufacturing, regulation and drug pricing.",
    "url": "https://finnhub.io/api/news?id=858a17d9a5f8021a7e35f74fb4df56b269a5d59d3a70662d788a98b907607c7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747424978,
      "headline": "Analysis-Novo Nordisk should look to the US for its next CEO, analysts say",
      "id": 134567760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market, analysts told Reuters.  Novo, which manufactures the popular weight-loss drug Wegovy, said on Friday its current CEO will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.  Financial analysts Reuters spoke with said an American may be better placed to deal with a Trump administration, which is rewriting the rules on pharmaceutical trade, manufacturing, regulation and drug pricing.",
      "url": "https://finnhub.io/api/news?id=858a17d9a5f8021a7e35f74fb4df56b269a5d59d3a70662d788a98b907607c7d"
    }
  },
  {
    "ts": null,
    "headline": "From insulin to Ozempic, history of Novo Nordisk's CEOs",
    "summary": "Jorgensen, who joined in 2017, has had the shortest tenure of all.  Danish couple August and Marie Krogh founded Nordsik Insulinlaboratorium in 1923 and commercialized the production of insulin.  The company competed with Novo Terapeutisk Laboratorium, which was founded by brothers Harald and Thorvald Pedersen, until the two merged in 1989.",
    "url": "https://finnhub.io/api/news?id=b545393dbf39812b39dfb33600214f2d7198e6d315d2d6e0aee568e0f15b5245",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747419466,
      "headline": "From insulin to Ozempic, history of Novo Nordisk's CEOs",
      "id": 134567761,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Jorgensen, who joined in 2017, has had the shortest tenure of all.  Danish couple August and Marie Krogh founded Nordsik Insulinlaboratorium in 1923 and commercialized the production of insulin.  The company competed with Novo Terapeutisk Laboratorium, which was founded by brothers Harald and Thorvald Pedersen, until the two merged in 1989.",
      "url": "https://finnhub.io/api/news?id=b545393dbf39812b39dfb33600214f2d7198e6d315d2d6e0aee568e0f15b5245"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's CEO Ousted: Deep-Value Opportunity With Sentiment Risks",
    "summary": "Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated look at NVO stock prospects.",
    "url": "https://finnhub.io/api/news?id=57e5aaf895c1427a927e0e97d7020fc8f5b0ea6eb2ff3d6043bc8456e27a76cc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747419307,
      "headline": "Novo Nordisk's CEO Ousted: Deep-Value Opportunity With Sentiment Risks",
      "id": 134513659,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/149452581/image_149452581.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated look at NVO stock prospects.",
      "url": "https://finnhub.io/api/news?id=57e5aaf895c1427a927e0e97d7020fc8f5b0ea6eb2ff3d6043bc8456e27a76cc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly strikes $1.3bn gene therapy deal with Rznomics",
    "summary": "The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.",
    "url": "https://finnhub.io/api/news?id=84fe7334351fe472ca78ed29eb06d15ab5cc11fc0ab4fe3369a1fb7a3b6ac36b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747416168,
      "headline": "Eli Lilly strikes $1.3bn gene therapy deal with Rznomics",
      "id": 134567762,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.",
      "url": "https://finnhub.io/api/news?id=84fe7334351fe472ca78ed29eb06d15ab5cc11fc0ab4fe3369a1fb7a3b6ac36b"
    }
  },
  {
    "ts": null,
    "headline": "Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic",
    "summary": "Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY) getting a lift after Novo Nordisk (NVO) pushed out its CEO Lars Fruergaard Jørgensen, and Virgin Galactic (SPCE) forecasting passenger space flights in the fall of 2026. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=0bd4f2b00fe34395a280493ea7c472364eff0f436c7c74b752320acb8b138420",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747415597,
      "headline": "Galaxy Digital on the Nasdaq, Novo ousts CEO, Virgin Galactic",
      "id": 134500286,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY) getting a lift after Novo Nordisk (NVO) pushed out its CEO Lars Fruergaard Jørgensen, and Virgin Galactic (SPCE) forecasting passenger space flights in the fall of 2026. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=0bd4f2b00fe34395a280493ea7c472364eff0f436c7c74b752320acb8b138420"
    }
  },
  {
    "ts": null,
    "headline": "Zealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is Pricey",
    "summary": "Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF market potential and challenges.",
    "url": "https://finnhub.io/api/news?id=5655f130d51431b7f8f9e712a52fdd4e1243d659e3727bde978bdab4cc77f057",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747412683,
      "headline": "Zealand: Promising Roche-Partnered Obesity Drug Developer - But Stock Is Pricey",
      "id": 134508338,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1886168190/image_1886168190.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF market potential and challenges.",
      "url": "https://finnhub.io/api/news?id=5655f130d51431b7f8f9e712a52fdd4e1243d659e3727bde978bdab4cc77f057"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound",
    "summary": "Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound",
    "url": "https://finnhub.io/api/news?id=22bfffc0df9cd57b724d703e4a8cfaef0bbe5acc57aec66a60f8c41dda7ab017",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747412525,
      "headline": "Eli Lilly: Obesity Drug Development To Go Beyond That Of Zepbound",
      "id": 134508346,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=22bfffc0df9cd57b724d703e4a8cfaef0bbe5acc57aec66a60f8c41dda7ab017"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock: Seems Like A No-Brainer At These Levels",
    "summary": "Novo Nordisk Stock: Seems Like A No-Brainer At These Levels",
    "url": "https://finnhub.io/api/news?id=b8ca36e1ed4b9c601b1eece657aee8bbe900dba4fbf1d4542d11dab959719262",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747409204,
      "headline": "Novo Nordisk Stock: Seems Like A No-Brainer At These Levels",
      "id": 134505125,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=b8ca36e1ed4b9c601b1eece657aee8bbe900dba4fbf1d4542d11dab959719262"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
    "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
    "url": "https://finnhub.io/api/news?id=8bbb3c23069a29fce289fbaaa27ca4e5be52498ccd00fecdf66efd86c9743dd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747407647,
      "headline": "Novo Nordisk Sheds 3% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
      "id": 134567764,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
      "url": "https://finnhub.io/api/news?id=8bbb3c23069a29fce289fbaaa27ca4e5be52498ccd00fecdf66efd86c9743dd2"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
    "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
    "url": "https://finnhub.io/api/news?id=877bc09696e8f170a9d6d280e99f7a2a4dab17a4ef23d09e511e249658d289f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747407647,
      "headline": "Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price",
      "id": 134498545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.",
      "url": "https://finnhub.io/api/news?id=877bc09696e8f170a9d6d280e99f7a2a4dab17a4ef23d09e511e249658d289f4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Turnaround Story Is Stronger Than You Think",
    "summary": "Pfizer's Turnaround Story Is Stronger Than You Think",
    "url": "https://finnhub.io/api/news?id=f1aa39358b70fbcabefaa095b1113b67f395143069dd178c847bce24ceee8311",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747405928,
      "headline": "Pfizer's Turnaround Story Is Stronger Than You Think",
      "id": 134500844,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f1aa39358b70fbcabefaa095b1113b67f395143069dd178c847bce24ceee8311"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.",
    "summary": "It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.",
    "url": "https://finnhub.io/api/news?id=b47d96f77a10b02a0c50e0804a3a09264d1cd43440b63ae2f931c3ab87dc0d53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747405620,
      "headline": "Novo Nordisk Boots CEO After Stock Falls 50%. It’s an Unusual Move for the Wegovy Drugmaker.",
      "id": 134498546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.",
      "url": "https://finnhub.io/api/news?id=b47d96f77a10b02a0c50e0804a3a09264d1cd43440b63ae2f931c3ab87dc0d53"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic boss sacked after falling behind in weight-loss race",
    "summary": "The boss of the drugs giant Novo Nordisk has been sacked after falling behind in the global race to develop weight-loss medication.",
    "url": "https://finnhub.io/api/news?id=5909d44439339c1fd36a59ec605c9801f659e33681c83268e0675affc80e8bfa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747403890,
      "headline": "Ozempic boss sacked after falling behind in weight-loss race",
      "id": 134498547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The boss of the drugs giant Novo Nordisk has been sacked after falling behind in the global race to develop weight-loss medication.",
      "url": "https://finnhub.io/api/news?id=5909d44439339c1fd36a59ec605c9801f659e33681c83268e0675affc80e8bfa"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?",
    "summary": "Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.",
    "url": "https://finnhub.io/api/news?id=2c25d887cc817aa08f49e2a080ef2b1154bc11a67dc5ad4421d01f7230fee0b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747400820,
      "headline": "Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?",
      "id": 134498548,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.",
      "url": "https://finnhub.io/api/news?id=2c25d887cc817aa08f49e2a080ef2b1154bc11a67dc5ad4421d01f7230fee0b1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=8df919f5d84928b73c5c3cee6aa06a4f72b49f021901dee2034a7c38140fe745",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747400414,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 134498549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=8df919f5d84928b73c5c3cee6aa06a4f72b49f021901dee2034a7c38140fe745"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker",
    "summary": "Novo Nordisk CEO Lars Fruergaard Jørgensen steps down from the Danish drug giant.",
    "url": "https://finnhub.io/api/news?id=592ec86504551d4d25d3bd1a5dfeb9d3fbb80f0336668b1a442847e24feb33e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747399762,
      "headline": "Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker",
      "id": 134498550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk CEO Lars Fruergaard Jørgensen steps down from the Danish drug giant.",
      "url": "https://finnhub.io/api/news?id=592ec86504551d4d25d3bd1a5dfeb9d3fbb80f0336668b1a442847e24feb33e1"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months",
    "summary": "Many Wall Street analysts think Novo Nordisk will make a solid rebound over the next 12 months.  The company may have promising new drugs on the way, including an oral version of semaglutide.  The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer.",
    "url": "https://finnhub.io/api/news?id=a835b4c15927ba78bf7d03cdadd30c66bac10b7fc97d8d4771b6fdb8f6181722",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747385220,
      "headline": "Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months",
      "id": 134498551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Many Wall Street analysts think Novo Nordisk will make a solid rebound over the next 12 months.  The company may have promising new drugs on the way, including an oral version of semaglutide.  The Denmark-based drugmaker's share price has plunged roughly 55% below its high set last summer.",
      "url": "https://finnhub.io/api/news?id=a835b4c15927ba78bf7d03cdadd30c66bac10b7fc97d8d4771b6fdb8f6181722"
    }
  }
]